

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### A Comparison study of effectiveness of pentoxifyllin and LD in preventing recurrent endometriosis

#### Protocol summary

##### Summary

This study was aimed to compare effect of 3 different medications regimens (pentoxifyllin, pentoxifyllin+LD, LD) on prevention of recurrence of endometriosis pain. This is a clinical trial performed on 83 patients with the chief complaint of pain (dysmenorrheal /or pelvic pain) after definite diagnosis of endometriosis by laparoscopy. Patients entered the study after simple sampling, and were allocated into 3 groups, treated with pentoxifyllin, pentoxifyllin + LD and LD alone for 6 months. Pain severity was assessed pre and post intervention by Visual Analogue Scale. In addition, pain was compared between 3 groups.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201109087513N1**

Registration date: **2012-05-02, 1391/02/13**

Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2012-05-02, 1391/02/13

##### Registrant information

##### Name

Hatav Ghasemi Tehrani

##### Name of organization / entity

Isfahan University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 913 113 4081

##### Email address

tehrani@med.mui.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Isfahan University of Medical Sciences -Research council

##### Expected recruitment start date

2008-03-01, 1386/12/11

##### Expected recruitment end date

2009-12-22, 1388/10/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

A Comparison study of effectiveness of pentoxifyllin and LD in preventing recurrent endometriosis

##### Public title

Effectiveness of pentoxifyllin on recurrence endometriosis

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria: Diagnosed Laparoscopic endometriosis with the clinical symptoms Exclusion criteria:Refusing the patient of entry to the protocol; The presence of the specific drug side effects

##### Age

From **25 years** old to **28 years** old

##### Gender

Female

##### Phase

4

##### Groups that have been masked

*No information*

##### Sample size

Target sample size: **83**

##### Randomization (investigator's opinion)

Randomized

## Randomization description

### Blinding (investigator's opinion)

Double blinded

### Blinding description

#### Placebo

Not used

#### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Isfahan University of Medical Sciences

##### Street address

Hezar Jerib Street, Isfahan University of Medical Sciences

##### City

Isfahan

##### Postal code

8184851153

#### Approval date

2007-02-10, 1385/11/21

#### Ethics committee reference number

387228

## Health conditions studied

### 1

#### Description of health condition studied

Endometriosis of uterus

#### ICD-10 code

N80

#### ICD-10 code description

Endometriosis of uterus

## Primary outcomes

### 1

#### Description

Pain reilief

#### Timepoint

6months

#### Method of measurement

Visual Analog Scale(VAS)

### 2

#### Description

endometriosis recurrence

#### Timepoint

after 6 months of follow up

#### Method of measurement

clinical assessment

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

We used the visual analog scale (VAS) method for detecting the severity of the possible pain existence before and after the treatment period (the recurrence).Each treatment duration was about 6months. Each protocol was described clearly for each patient and finally the three groups were constructed as below: Group one: 800 mgs of Pentoxifyllin in two divided doses (capsules of 400mgs) daily.

#### Category

Treatment - Drugs

### 2

#### Description

Group two: Pentoxifyllin capsules with the same dose plus OCP (LD) one tablet per night, from the third day of the menstrual cycle for 6 months.

#### Category

Treatment - Drugs

### 3

#### Description

Group three: OCP (LD) one tablet per night for21days then 7days rest and repaet it for 6 months

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Shahid Beheshti Hospital

##### Full name of responsible person

Mojdeh Ghasemi

##### Street address

Felezi Bridge-Beheshti Hospital

##### City

Isfahan

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Isfahan University of Medical Sciences-Research Council

##### Full name of responsible person

Dr. Peyman Adibi

**Street address**

No.4, Research Building, Isfahan University of Medical Sciences, Hezar jerib St.

**City**

Isfahan

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Isfahan University of Medical Sciences-Research Council

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Isfahan University of Medical Sciences

**Full name of responsible person**

Mojdeh Ghasemi

**Position**

Midwife, Head of Research Office

**Other areas of specialty/work**

**Street address**

Research Office, Shahid Beheshti hospital, Flezi Bridge

**City**

Isfahan

**Postal code**

8184851153

**Phone**

+98 913 319 1159

**Fax**

+98 31 1236 4210

**Email**

md\_ghasemi@yahoo.com/  
research\_beheshti@med.mui.ac.ir

**Web page address**

www.mui.ac.ir

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Isfahan University of Medical Sciences

**Full name of responsible person**

Dr. Ata alah Ghahiri

**Position**

Associated Professor

**Other areas of specialty/work**

**Street address**

Ob& Gyn Dept, Alzahra Hospital, Sofe st.

**City**

Isfahan

**Postal code**

**Phone**

+98 913 119 0117

**Fax**

+98 31 1236 2191

**Email**

ghahiri@med.mui.ac.ir

**Web page address**

www.mui.ac.ir

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Isfahan University of Medical Sciences

**Full name of responsible person**

Moje Ghasemi

**Position**

Midwife

**Other areas of specialty/work**

**Street address**

Shahid Beheshti Hospital, Flezi Bridge

**City**

Isfahan

**Postal code**

8184851153

**Phone**

+98 31 1236 7001

**Fax**

+98 31 1236 4210

**Email**

md\_ghasemi@yahoo.com/  
research\_beheshti@med.mui.ac.ir

**Web page address**

www.mui.ac.ir

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*